

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA23; The use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

This guidance was issued April 2001 with a review date of February 2011

Background

At the GE meeting of 15 March 2011 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	The decision to review the guidance should be deferred to 2015.
Rationale for selecting this proposal	NICE will reconsider whether a review is necessary at the specified date, alongside the decision to review TA121

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	The decision to review the guidance should be deferred to 2015. In the meantime, TA23 will be placed on the 'static guidance list'
------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------

Respondent	Response to proposal	Details	Comment from Technology Appraisals
The Brain and Spine Foundation	Agree	<p>We are not aware of any new evidence regarding the use of Temozolomide for the treatment of recurrent malignant gliomas.</p> <p>So we agree with postponing the review until 2015, when we hope there will be supporting evidence to markedly change this guideline.</p>	Comment noted.
Department of Health	No comment		Noted.
Healthcare Improvement Scotland	No comment		Noted.
Medicines and Healthcare products Regulatory Agency (MHRA)	No objection	<p>We don't have any information that affects the proposal to postpone a review of the guidance. We are not aware of new information that impinges on the April 2001 guidance on temozolomide for recurrent malignant glioma.</p> <p>The relevant licensed indication for temozolomide is: treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.</p>	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
The Royal College of Nursing	Agree	<p>Nurses caring for people with glioma were invited to comment on NICE's proposal to defer the review of the Technology Appraisal Guidance No. 23 on the use of temozolomide for the treatment of recurrent malignant glioma.</p> <p>They are not aware of any new evidence regarding the use of Temozolomide for the treatment of recurrent malignant glioma.</p> <p>They agree that the review should be postponed until 2015, when it is hoped there will be supporting evidence to markedly change this guidance. There are no further comments to make on behalf of the RCN.</p>	Comment noted.

Respondent	Response to proposal	Details	Comment from Technology Appraisals
National Cancer Research Institute/ Royal College of Physicians/ Royal College of Radiologists/ Association of Cancer Physicians/ Joint Collegiate Council for Oncology	Agree	NCRI/RCP/RCR/ACP/JCCO have reviewed this proposal and agree that the appraisal should be deferred.	Comment noted.

No response received from:

<u>Manufacturers/sponsors</u>	<u>General</u>
<ul style="list-style-type: none"> • Hospira (temozolomide) • Medac (temozolomide) • Merck Sharp and Dohme (temozolomide) • Mylan (temozolomide) • Ratiopharm (temozolomide) • Sandoz (temozolomide) • Teva (temozolomide) 	<ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • National Association of Primary Care • NHS Alliance

Patient/carer groups

- Afiya Trust
- Black Health Agency
- Brainstrust
- Brain Tumour UK
- British Brain Tumour Association
- CANCERactive
- Cancer Black Care
- Cancer Equality
- Cancer 52
- Chinese National Healthy Living Centre
- Counsel and Care
- Equalities National Council
- Helen Rollason Heal Cancer Trust
- Macmillan Cancer Support
- Marie Curie Cancer Care
- Muslim Council of Britain
- Muslim Health Network
- Neurological Alliance
- Neurosupport
- Rarer Cancers Foundation
- Samantha Dickson Brain Tumour Trust
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Sue Ryder Care
- Tenovus

- NHS Commercial Medicines Unit
- NHS Confederation
- Public Health Wales NHS Trust
- Scottish Medicines Consortium

Comparator manufacturers

- Alliance Pharmaceuticals (procarbazine)
- Archimedes Pharmaceuticals (carmustine implants)
- Bristol-Myers Squibb Pharmaceuticals (carmustine)
- Genus Pharmaceuticals (vincristine sulphate)
- Hospira UK (vincristine)
- Medac UK (lomustine)
- Teva UK (vincristine)

Relevant research groups

- Brain Tumour Research
- British Neurological Research Trust
- Department of Neurological Science, University of Liverpool
- Institute of Cancer Research
- MRC Clinical Trials Unit
- National Institute for Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute for the Care of Older People

Professional groups

- Association of British Neurologists
- Association of Surgeons of Great Britain and Ireland
- British Association for Services to the Elderly
- British Association of Surgical Oncology
- British Geriatrics Society
- British Neuropathological Society
- British Oncological Association
- British Psychosocial Oncology Society
- Cancer Networks Pharmacists Forum
- Cancer Research UK
- Institute of Neurology
- Primary Care Neurology Society
- Royal College of Anaesthetists
- Royal College of General Practitioners
- Royal College of Pathologists
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society of British Neurological Surgeons
- United Kingdom Clinical Pharmacy Association

Others

- NHS Wiltshire
- NHS Wirral
- Welsh Assembly Government

Assessment Group

- Assessment Group tbc
- National Institute for Health Research Health Technology Assessment

Associated Guideline Group

- National Collaborating Centre for Cancer

Associated Public Health Groups

- tbc

GE paper sign-off: Janet Robertson, Associate Director – Technology Appraisals Programme

Contributors to this paper:

Technical Lead: Scott Goulden

Technical Adviser: Zoe Charles

Project Manager: Arrezou Zareian

28 April 2011